Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-008220
Filing Date
2021-02-05
Accepted
2021-02-05 17:41:38
Documents
1
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 5 SUBMISSION doc5.html 5  
1 FORM 5 SUBMISSION doc5.xml 5 48970
  Complete submission text file 0001209191-21-008220.txt   50300
Mailing Address 1207 17TH AVENUE SUITE 103 NASHVILLE TN 37212
Business Address
KAZIMI A J (Reporting) CIK: 0001075050 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-33637 | Film No.: 21597547

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations